Gil Yosipovitch, MD

An expert discusses how barzolvolimab's unique mast cell-targeting mechanism, rapid efficacy, and potential disease-modifying effects position it as a promising treatment option for CSU patients who fail antihistamines or omalizumab therapy.

An expert discusses how barzolvolimab's safety profile includes manageable adverse events such as minimal and reversible hair color changes, mild neutropenia, and skin hyperpigmentation that are not clinically concerning.

An expert discusses how barzolvolimab demonstrated statistically significant and clinically meaningful reductions in UAS7 scores, with over 50% of patients achieving complete response and sustained disease control lasting 28 weeks after the final dose.

An expert discusses how the barzolvolimab phase 2 trial was a 76-week randomized, double-blind, placebo-controlled study testing different doses in patients with moderate to severe CSU, including those previously treated with omalizumab.

An expert discusses how to approach treatment selection in a 68-year-old Latino patient with multiple comorbidities, including chronic kidney disease, emphasizing the importance of considering injection frequency preferences, treatment burden, and the excellent safety profile of targeted biologics in older patients with complex medical histories.

An expert discusses how to manage a 32-year-old man with both prurigo nodularis and atopic dermatitis who also has asthma, explaining why dupilumab would be the preferred treatment choice over nemolizumab due to safety concerns regarding asthma exacerbation with the latter medication.

An expert discusses how to approach a 58-year-old African American woman with severe prurigo nodularis experiencing extreme itch (9/10 rating) and extensive lesions, emphasizing the need for rapid systemic intervention with nemolizumab due to its faster onset of itch relief compared with other biologics.

An expert discusses how the evolving CSU treatment landscape includes H1 antihistamines as first-line therapy, omalizumab as second-line, and emerging treatments like dupilumab, remibrutinib, and barzolvolimab that target different mechanisms including mast cell depletion.

An expert discusses how chronic spontaneous urticaria is a recurrent inflammatory skin condition causing itchy wheals and angioedema that significantly impacts patients' quality of life, sleep, and emotional well-being.

An expert discusses how prurigo nodularis represents one of the most severe itching conditions in dermatology, significantly impacting patients' quality of life and sleep, and explains the importance of breaking the itch-scratch cycle while highlighting recent treatment advances with targeted biologics like dupilumab and nemolizumab.

At the 2025 Revolutionizing Atopic Dermatitis Conference, Gil Yosipovitch, MD, explored the pathophysiology of chronic itch through the lens of type 2 cytokine inhibition, neuromodulatory therapies, and more.

Gil Yosipovitch, MD, reviews differences including lesion appearance, cytokine pathways, treatment options, and more.

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Gil Yosipovitch, MD, discusses the correlation between increased BNP levels and chronic pruritus of unknown origin.

Step therapy policies place a large administrative burden on physicians, which, in turn, takes time away from patient care. Some states are working on legislation that seeks to regulate step therapy protocols and ensure they are safe for patients.